^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gastrointestinal Stromal Tumor
    Drug:sunitinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    SUTENT is a kinase inhibitor indicated for:...the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Gastrointestinal Stromal Tumors: Systemic Therapy agents and regimens for unresectable GIST with significant morbidity…Preferred Regimen…Sunitinib (category 1)
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Gastrointestinal Stromal Tumors: Systemic Therapy agents and regimens for unresectable GIST with significant morbidity...Useful in certain circumstances…Everolimus + TKI…TKIs to be considered for use in combination with everolimus include imatinib, sunitinib, or regorafenib
    Secondary therapy:
    everolimus